28732-79-8

Basic information

• Product Name: 4-CHLOROPYRIDO[2,3-D]PYRIMIDINE
• Synonyms: 4-CHLOROPYRIDO[2,3-D]PYRIMIDINE;Pyrido[2,3-d]pyrimidine, 4-chloro-;4-Chloropyrido[2,3-d]pyri...;4-chloropyrido[2;4-Chloropyrido[2,3-d]pyriMidin
• CAS NO: 28732-79-8
• Molecular Formula: C₇H₄ClN₃
• Molecular Weight: 165.58
• Product Categories: CHIRAL CHEMICALS;pyrimidine;Heterocycle-Pyrimidine series
• Mol File: 28732-79-8.mol
• Article Data: 11

Chemical Properties

• Melting Point: 137-138 °C (decomp)(Solv: heptane (142-82-5))
• Boiling Point: 297.293 °C at 760 mmHg
• Flash Point: 161.721 °C
• Appearance: /
• Density: 1.438 g/cm³
• Vapor Pressure: 0.00241mmHg at 25°C
• Refractive Index: 1.674
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: 0.84±0.30(Predicted)
• CAS DataBase Reference: 4-CHLOROPYRIDO[2,3-D]PYRIMIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-CHLOROPYRIDO[2,3-D]PYRIMIDINE(28732-79-8)
• EPA Substance Registry System: 4-CHLOROPYRIDO[2,3-D]PYRIMIDINE(28732-79-8)

Safety Data

• Hazardous Substances Data: 28732-79-8(Hazardous Substances Data)

Usage

Uses

4-Chloropyrido[2,3-D]pyrimidine is used in preparation of 1,8-naphthyridine compounds as ανβ6 integrin inhibitors useful for treating fibrosis.

InChI:InChI=1/C7H4ClN3/c8-6-5-2-1-3-9-7(5)11-4-10-6/h1-4H

Upstream product

• 24410-19-3 4-hydroxypyrido[2,3-d]pyrimidine 
• 5345-47-1 2-aminopyridin-3-carboxylic acid 
• 7463-30-1 N-(2-pyridyl-3-methyl)acetamide 
• 21038-66-4 2,4-dihydroxy-pyrido[2,3-d]pyrimidine 
• 24410-19-3 3H-pyrido[2,3-d]pyrimidin-4-one 

Downstream Products

• 130015-65-5 4-p-Chlorophenylaminopyrido<2,3-d>pyrimidine 
• 1201580-99-5 4-[(R)-2-(2-chlorophenoxymethyl)pyrrolidin-1-yl]-pyrido[2,3-d]pyrimidine 
• 853680-72-5 (2R)-{1-(4-chlorobenzyl)-2-oxo-2-[4-(5,6,7,8-tetrahydro-pyrido[2,3-d]pyrimidin-4-yl)-piperazin-1-yl]-ethyl}-carbamic acid tert-butyl ester 
• 108902-48-3 phenyl-pyrido[2,3-d]pyrimidin-4-yl-amine 
• 186519-49-3 (3-chloro-phenyl)-(pyrido[2,3-d]pyrimidin-4-yl)-amine 
• 37538-65-1 4-aminopyrido[2,3-d]pyrimidine 

Relevant articles and documents

ION CHANNEL INHIBITOR COMPOUNDS FOR CANCER TREATMENT

The present invention concerns a compound of following general formula (I): where: either R is an R1 group and R′ is an -A1-Cy1 group, or R is an -A1-Cy1 group and R′ is an R1 group, R1 particularly being H or (C1-C6)alkyl group;A1 being an —NH— radical or —NH—CH2— radical;Cy1 particularly being a phenyl group,A is a fused (hetero)aromatic ring having 5 to 7 atoms, for use for treating cancer.

Pharmacophore requirements for HIV-1 reverse transcriptase inhibitors that selectively “Freeze” the pre-translocated complex during the polymerization catalytic cycle

Reverse transcriptase (RT) is responsible for replicating the HIV-1 genome and is a validated therapeutic target for the treatment of HIV infections. During each cycle of the RT-catalyzed DNA polymerization process, inorganic pyrophosphate is released as the by-product of nucleotide incorporation. Small molecules were identified that act as bioisosteres of pyrophosphate and can selectively freeze the catalytic cycle of HIV-1 RT at the pre-translocated stage of the DNA- or RNA-template-primer-enzyme complex.

Solvent-free or low-solvent large-scale preparation of chloropyrimidine and analogues

Chloropyrimidine or other N-containing aromatic heterocyclic analogues can be efficiently prepared from the corresponding hydroxylated precursors under solvent-free or low-solvent conditions with equimolar or less chlorinating reagents. This high-yielding protocol allows successful preparations of multigram and kilogram batches of these important synthetic intermediates.